June 17, 2020 -- Yumab has announced that the first financing round of its spinoff Corat Therapeutics will be used to advance the development of COVID-19 antibody drug candidates.
Corat will continue the preclinical development of the lead antibody drug candidate for COVID-19, which was identified using Yumab's discovery of fully human monoclonal antibodies that neutralized activity against live SARS-CoV-2. Corat's efforts are led by managing director Thomas Schirrmann, PhD.
Clinical development may begin by the end of 2020, according to the company.